Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non–small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non–small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study

Authors:	Mahmut Gümü? MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüro?lu MD Miranda Gogishvili MD Haci M Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J S Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD

Affiliation:	1. Istanbul Medeniyet University, Faculty of Medicine, Istanbul, Turkey;2. Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA;3. IQVIA, Amsterdam, The Netherlands;4. Department of Medical Oncology, Istinye University Faculty of Medicine Liv Hospital, Ankara, Turkey;5. Dnipropetrovsk State Medical Academy, City Multifield Clinical Hospital, Dnipropetrovsk, Ukraine;6. Cerrahpa?a Medical Faculty, Istanbul University-Cerrahpa?a, Istanbul, Turkey;7. High Technology Medical Centre, Tbilisi, Georgia;8. Department of Medical Oncology, Bezmialem Vakif University, Medical Faculty, Istanbul, Turkey;9. Department of Medical Oncology, Trakya University, ?skender/Edirne Merkez/Edirne, Turkey;10. IQVIA, Reading, UK;11. Sanofi, Reading, UK;12. Sanofi, Bridgewater, New Jersey, USA;13. Sanofi, Cambridge, Massachusetts, USA;14. Department of Medical Oncology, Ba?kent University, Etimesgut, Ankara, Turkey

Abstract:

Keywords:	cemiplimab non-small cell lung cancer patient-reported outcomes quality of life symptom burden

设为首页 | 免责声明 | 关于勤云 | 加入收藏